German chemical/pharmaceutical major Hoechst's South African subsidiary, Hoechst SA, is going to be listed on the Johannesburg Stock Exchange. The motivation to list shares of Hoechst SA has been driven by Hoechst's desire to strengthen its capital base for its future expansion within South Africa, and to provide local investors with the opportunity to invest in the group and participate in its future growth.
Reinhard Traub, managing director of Hoechst SA, pointed out that Hoechst established its first operation in South Africa in 1957, and the move to be quoted on the JSE reinforces its commitment to the country. Hoechst SA will be the second-largest listing of a Hoechst subsidiary in the world, the largest being SGL Carbon AG, which was recently quoted in both Germany and the USA.
Mr Traub said Hoechst is a major player in the South African pharmaceutical and chemical industry, with sales in 1994 reaching around 1.5 billion rand ($414 million). In addition, indent sales of Hoechst AG amount to some 200 million rand ($55.2 million) a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze